← Eichor
Condition: Peripheral T Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04045470A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07293403MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular H
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05572983SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06122389A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Phase 1 · 3 location(s) · Memorial Sloan Kettering Cancer Center · NCT05296304"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Phase 1/Phase 2 · 1 location(s) · Mingzhi Zhang · NCT06559553Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Go-CHOP as the Frontline Therapy for PTCL
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05963347Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Pr
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05958719Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106Genotype-guided Treatment in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT05675813GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NA · 1 location(s) · Ruijin Hospital · NCT05662540Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06824883A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04365036A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07047885A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Perip
Phase 3 · 1 location(s) · Evopoint Biosciences Inc. · NCT06776952A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of New
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06630091Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05956041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.